## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002.

Nan	ne of	en	tity
-----	-------	----	------

## LIVING CELL TECHNOLOGIES LIMITED

ABN

14 104 028 042

We (the entity) give ASX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

**ORDINARY SHARES** 

Number of +securities issued or to be issued (if known) or maximum number which may be issued 5,752,312

3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

PARI PASSU TO EXISTING SECURITIES

11/3/2002 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

YES Do the \*securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment \$0.01 PER SHARE 5 Issue price or consideration Purpose of the issue ISSUE OF SHARES TO THE HOLDERS (If issued as consideration for the OF CONVERTIBLE NOTES IN THE acquisition of assets, clearly identify PROPORTIONS THAT THE NOTES ARE those assets) HELD 7 Dates of entering +securities into 31 JANUARY 2008 uncertificated holdings or despatch of certificates

8	Number	and	+clas	s c	of all
	+securities	quo	oted	on	ASX
	(including	the se	ecuritie	es in	clause
	2 if applica	able)			

Number	+Class
199,068,054	ORDINARY SHARES

9. Number and \*class of all \*securities not quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
Number	+Class BALANCE BROUGHT
7,970,000	FORWARD AT 31/01/08
	MOVEMENTS IN EMPLOYEE OPTIONS
	SINCE LAST 3B (05/12/07):
NIL	GRANTED
NIL	LAPSED & FORFEITED
NIL	EXERCISED
	BALANCE (CURRENT) OF
	EMPLOYEE OPTIONS OVER UNISSUED
7,970,000	ORDINARY SHARES
	BALANCE (BROUGHT FORWARD):
3,600,000	A CLASS OPTIONS
8,723,650	B CLASS OPTIONS
1,873,250	C CLASS OPTIONS
3,000,000	D CLASS OPTIONS
1,300,264	HC OPTIONS
18,497,164	TOTAL
NIL	GRANTED
NIL	LAPSED & FORFEITED
NIL	EXERCISED
3,600,000	BALANCE (CURRENT): A CLASS OPTIONS
8,723,650	B CLASS OPTIONS
1,873,250	C CLASS OPTIONS
3,000,000	D CLASS OPTIONS
1,300,264	HC OPTIONS
18,497,164	TOTAL
11,736,000	CONVERTIBLE NOTES
3,322,868	WARRANTS – BEING:
3,322,000	B/F APPROX 8,800,000
	ACTUAL FIGURE IS 8,977,180
	ACTUAL FIGURE IS
	ACTUAL FIGURE IS 8,977,180 OF WHICH 5,752,312 HAVE BEEN EXERCISED AND 3,224,868 ARE
	ACTUAL FIGURE IS 8,977,180 OF WHICH 5,752,312 HAVE BEEN EXERCISED AND 3,224,868 ARE SUBJECT TO SHAREHOLDERS
	ACTUAL FIGURE IS 8,977,180 OF WHICH 5,752,312 HAVE BEEN EXERCISED AND 3,224,868 ARE SUBJECT TO

11/3/2002 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	
--	--

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A

25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements in full through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Despatch date	N/A
	3 - Quotation of securitied only complete this section if you are appo	
34	Type of securities (tick one)	
(a)	✓ Securities described in Part 1	
(b)		of the escrowed period, partly paid securities that become fully paid, employed ends, securities issued on expiry or conversion of convertible securities
Entiti	es that have ticked box 34(a)	

## Additional securities forming a new class of securities

(If the additional securities do not form a new class, go to 43)

11/3/2002 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

Tick to docume	to indicate you are providing the information or uments			
35	1 1	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution *securities setting out the number of holders in the cate 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over			
37	A copy of any trust deed for the additional +securities			
(now go	v go to 43)			
Entitie	tities that have ticked box 34(b)			
38	Number of securities for which <sup>+</sup> quotation is sought			
39	Class of *securities for which quotation is sought			
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?			
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	now  Example: In the case of restricted securities, end of			
	restriction period  (if issued upon conversion of another security, clearly identify that other security)			

Number and \*class of all \*securities quoted on ASX (*including* the securities in clause 38)

+Class

(now go to 43)

### All entities

### **Fees**

43	Payment method (tick one)		
	✓	Tax invoice requested	
		Electronic payment made  Note: Payment may be made electronically if Appendix 3B is given to ASX electronically at the same time.	
		Periodic payment as agreed with the home branch has been arranged  Note: Arrangements can be made for employee incentive schemes that involve frequent issues of securities.	

## **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the \*securities to be quoted, it has been provided at the time that we request that the \*securities be quoted.

+ See chapter 19 for defined terms.

11/3/2002 Appendix 3B Page 7

- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == == ==

Sign here:	[original signed] Company Secretary	Date:	31/01/ 2008
Print name:	N J V Geddes		

LC7<sup>.</sup>

**Living Cell Technologies Ltd** 

PO Box 3014, Auburn VIC 3123

ABN: 14 104 028 042

31 January 2008

Relief Under Section 708A(5)(e) of the Corporations Act 2001

Living Cell Technologies Limited (the Company) issued 5,752,312 fully paid ordinary shares in the Company (Shares) to the holders of convertible notes in the proportions that

the notes are held.

The Company relies on case 1 in Section 708A(5) of the Corporations Act 2001 (Cth) (Corporations Act) in respect of the issue of the Shares and gives notice under paragraph

708A(5)(e) of Section 708A of the Corporations Act of the following details:

the Company has issued the Shares without a disclosure document for the Shares

being prepared in accordance with Part 6D.2 of the Corporations Act;

as at the date of this notice, the Company has complied with the provisions of

Chapter 2M of the Corporations Act (as applicable to the Company);

Section 674 of the Corporations Act; and

at the date of this notice, there is no information to be disclosed which is "excluded

information" (as defined in paragraph 708A(7) of the Corporations Act) which would

be reasonable for investors and their professional advisers to expect to find in a

disclosure document.

Ends

For further enquiries:

NJV Geddes

Company Secretary

02 9252 1933